122 related articles for article (PubMed ID: 38871536)
1. Corrigendum to "Correlation between fractional flow reserve and imaging findings during drug-coated balloon treatment for femoropopliteal diseases" [Cardiovascular Revascularization Medicine 60 (2024) 66-71].
Iwasaki Y; Shimada T; Sato T; Koike J; Funatsu A; Kobayashi T; Ikeda T; Nakamura S
Cardiovasc Revasc Med; 2024 Jun; ():. PubMed ID: 38871536
[No Abstract] [Full Text] [Related]
2. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial.
Vos NS; Fagel ND; Amoroso G; Herrman JR; Patterson MS; Piers LH; van der Schaaf RJ; Slagboom T; Vink MA
JACC Cardiovasc Interv; 2019 Sep; 12(17):1691-1699. PubMed ID: 31126887
[TBL] [Abstract][Full Text] [Related]
4. Correlation between physiological assessment and imaging findings during drug-coated balloon treatment for femoropopliteal diseases.
Iwasaki Y; Shimada T; Sato T; Koike J; Funatsu A; Kobayashi T; Ikeda T; Nakamura S
Cardiovasc Revasc Med; 2024 Mar; 60():66-71. PubMed ID: 37739885
[TBL] [Abstract][Full Text] [Related]
5. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
Sun G; Liu J; Jia S; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
Vascular; 2021 Jun; 29(3):340-349. PubMed ID: 32903168
[TBL] [Abstract][Full Text] [Related]
6. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
7. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
[TBL] [Abstract][Full Text] [Related]
8. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
Gurin MI; Beyer SE; Weinberg M; Parikh SA; Armstrong EJ; Albaghdadi MS; Aronow HD; Carroll BJ; Yeh R; Secemsky EA
J Endovasc Ther; 2021 Apr; 28(2):246-254. PubMed ID: 33426984
[TBL] [Abstract][Full Text] [Related]
9. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions.
Shin ES; Ann SH; Balbir Singh G; Lim KH; Kleber FX; Koo BK
Catheter Cardiovasc Interv; 2016 Aug; 88(2):193-200. PubMed ID: 26423017
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus-Coated Balloon in Femoropopliteal Steno-Occlusive Disease: Efficacy, Safety, and 1-Year Outcomes. An All-Comers Registry.
Franzese M; Pucciarelli A; Spione F; Salemme L; Popusoi G; Ferrone M; Gioia GD; Raj ER; Verdoliva S; Stabile E; Tesorio T; Cioppa A
J Endovasc Ther; 2023 Dec; ():15266028231217657. PubMed ID: 38084379
[TBL] [Abstract][Full Text] [Related]
11. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Micari A; Brodmann M; Keirse K; Peeters P; Tepe G; Frost M; Wang H; Zeller T;
JACC Cardiovasc Interv; 2018 May; 11(10):945-953. PubMed ID: 29798770
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
13. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
[TBL] [Abstract][Full Text] [Related]
14. Atherectomy plus drug-coated balloon versus drug-coated balloon only for treatment of femoropopliteal artery lesions: A systematic review and meta-analysis.
Lin F; Wang H; Ding W; Chen G; Zhang Z
Vascular; 2021 Dec; 29(6):883-896. PubMed ID: 33478353
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices.
Secemsky EA; Kundi H; Weinberg I; Jaff MR; Krawisz A; Parikh SA; Beckman JA; Mustapha J; Rosenfield K; Yeh RW
JAMA Cardiol; 2019 Apr; 4(4):332-340. PubMed ID: 30747949
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes.
Rodoplu O; Oztas DM; Meric M; Beyaz MO; Ulukan MO; Yildiz CE; Unal O; Ugurlucan M
Ann Vasc Surg; 2021 May; 73():222-233. PubMed ID: 33359329
[TBL] [Abstract][Full Text] [Related]
17. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
18. Network Meta-Analysis of All Available Regimens Based on Drug-Coated Balloon Angioplasty and Laser Atherectomy for Femoropopliteal In-Stent Restenosis.
Yu C; Tang W; Ren T; Chen Q; Lu R; Gao Y
J Endovasc Ther; 2024 Jun; 31(3):390-399. PubMed ID: 36189843
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions.
Ni L; Ye W; Zhang L; Jin X; Shu C; Jiang JS; Yang M; Wu DM; Li M; Yu GF; Yang J; Huang JH; Wang XB; Li XQ; Jiang WL; Wu ZQ; Liu CW
Front Cardiovasc Med; 2022; 9():821672. PubMed ID: 35391838
[TBL] [Abstract][Full Text] [Related]
20. Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Kavala AA; Kuserli Y; Turkyilmaz S
Vascular; 2021 Apr; 29(2):260-269. PubMed ID: 32838692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
